Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Yanqing Ding, Li He, Qingling Zhang, Zhongxi Huang, Xiaoyan Che, Jinlin Hou, Huijun Wang, Hong Shen, Liwen Qiu, Zhuguo Li, Jian Geng, Junjie Cai, Huixia Han, Xin Li, Wei Kang, Desheng Weng, Ping Liang, Shibo Jiang, Yanqing Ding, Li He, Qingling Zhang, Zhongxi Huang, Xiaoyan Che, Jinlin Hou, Huijun Wang, Hong Shen, Liwen Qiu, Zhuguo Li, Jian Geng, Junjie Cai, Huixia Han, Xin Li, Wei Kang, Desheng Weng, Ping Liang, Shibo Jiang

Abstract

We previously identified the major pathological changes in the respiratory and immune systems of patients who died of severe acute respiratory syndrome (SARS) but gained little information on the organ distribution of SARS-associated coronavirus (SARS-CoV). In the present study, we used a murine monoclonal antibody specific for SARS-CoV nucleoprotein, and probes specific for a SARS-CoV RNA polymerase gene fragment, for immunohistochemistry and in situ hybridization, respectively, to detect SARS-CoV systematically in tissues from patients who died of SARS. SARS-CoV was found in lung, trachea/bronchus, stomach, small intestine, distal convoluted renal tubule, sweat gland, parathyroid, pituitary, pancreas, adrenal gland, liver and cerebrum, but was not detected in oesophagus, spleen, lymph node, bone marrow, heart, aorta, cerebellum, thyroid, testis, ovary, uterus or muscle. These results suggest that, in addition to the respiratory system, the gastrointestinal tract and other organs with detectable SARS-CoV may also be targets of SARS-CoV infection. The pathological changes in these organs may be caused directly by the cytopathic effect mediated by local replication of the SARS-CoV; or indirectly as a result of systemic responses to respiratory failure or the harmful immune response induced by viral infection. In addition to viral spread through a respiratory route, SARS-CoV in the intestinal tract, kidney and sweat glands may be excreted via faeces, urine and sweat, thereby leading to virus transmission. This study provides important information for understanding the pathogenesis of SARS-CoV infection and sheds light on possible virus transmission pathways. This data will be useful for designing new strategies for prevention and treatment of SARS.

Copyright 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Figures

Figure 1
Figure 1
Detection of SARS‐CoV N protein by immunofluorescence. (A) Vero E6 cells infected by SARS‐CoV (×200). (B) Uninfected Vero E6 (×200); (C) 293 cells infected with adenovirus type 5 (×400). (D) MA104 cells infected by Group A rotavirus (×200). The green colour represents the positive signal for SARS‐CoV N protein, while the negative cells without SARS‐CoV infection display a red colour
Figure 2
Figure 2
Detection of SARS‐CoV in lung tissues from patients who died of SARS (A–F) and from a patient who died through rupture of a thoracic aortic aneurysm (G and H). (A) Viral inclusion body in a pneumocyte (arrow; H&E, ×400). (B) Viral inclusion body in a pneumocyte (arrow; Macchiavello's stain, ×400). (C) Clusters of corona‐like viral particles in the endoplasmic reticulum of a type II alveolar epithelial cell (transmission electron microscopy; bar = 200 nm); (D) SARS‐CoV M protein gene (a, 667bp) and RNA polymerase gene fragment (b, 190bp) detected in lung tissues from three SARS cases (1–3), but not in the negative control (N), who died through rupture of a thoracic aortic aneurysm (RT‐PCR). M = marker. (E) SARS‐CoV N protein expression in pneumocytes (IHC, ×400). (F) SARS‐CoV RNA polymerase gene expression in pneumocytes (ISH, ×400); the positive cells (brown‐yellow) are indicated by arrows. (G) SARS‐CoV N protein expression (IHC, ×200). (H) SARS‐CoV RNA polymerase gene expression (ISH, ×200) is not detectable in lung tissue from the individual who died through rupture of a thoracic aortic aneurysm
Figure 3
Figure 3
Detection of SARS‐CoV N protein by IHC (A and C) and of SARS‐CoV RNA polymerase gene fragments by ISH (B and D) in the following samples from SARS patients (A and B; DAB; figures 3, 7A, 8A, 10, 13 ×200; figures 1, 2, 4–6, 8B, 9, 11, 12 ×400; 7B ×480) and from control patients (C and D; DAB; figures 1–11 × 400). (1) Bronchial serous gland epithelium; (2) gastric parietal cells; (3) small intestinal epithelium; (4) acidophilic cells of parathyroid; (5) pancreatic acinar cells; (6) acidophilic cells of pituitary; (7) adrenal cortical cells; (8) sweat gland cells; (9) cerebral neurones; (10) epithelial cells of distal convoluted renal tubule; (11) hepatocytes near the central vein; (12) myocardium; (13) seminiferous tubules of testis. The brownish‐yellow colour in cells represents positive signal for SARS‐CoV N protein in IHC, and for SARS‐CoV RNA polymerase gene fragments in ISH

References

    1. WHO . Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. [2003].
    1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953–1966.
    1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967–1976.
    1. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319–1325.
    1. Marra MA, Jones SJM, Astell CR, et al. The genome sequence of the SARS‐associated coronavirus. Science 2003; 300: 1399–1404.
    1. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394–1399.
    1. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science 2003; 302: 276–278.
    1. Li WH, Moore MJ, Vasilieva NY, et al. Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450–454.
    1. Wong SK, Li W, Moore MJ, et al. A 193‐amino‐acid fragment of the SARS coronavirus S protein efficiently binds angiotensin‐converting enzyme 2. J Biol Chem 2003; 279: 3197–3201.
    1. Xiao X, Chakraborti S, Dimitrov AS, et al. The SARS‐CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003; 312: 1159–1164.
    1. Dimitrov DS. The secret life of ACE2 as a receptor for the SARS virus. Cell 2003; 115: 652–653.
    1. Liu S, Xiao G, Chen Y, et al. Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS‐associated coronavirus: implication for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004; 363: 938–947.
    1. Kuiken T, Fouchier RAM, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362: 263–270.
    1. Lin Y, Shen X, Yang RF, et al. Identification of an epitope of SARS‐coronavirus nucleocapsid protein. Cell Res 2003; 13: 141–145.
    1. WHO . Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). 2003.
    1. Macfie, N . China confirms SARS case in Southern Guangzhou. Reuters Health Information. 2004.
    1. Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003; 200: 282–289.
    1. Wang H, Ding Y, Li X, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349: 507–508.
    1. Che XY, Qiu LW, Pan YX, et al. Rapid and efficient preparation of monoclonal antibodies against SARS‐associated coronavirus nucleocapsid protein by immunizing mice. Di Yi Jun Yi Da Xue Xue Bao 2003; 23: 640–642.
    1. Lounsbury KM, Stern M, Taatjes D, et al. Increased localization and substrate activation of protein kinase C delta in lung epithelial cells following exposure to asbestos. Am J Pathol 2002; 160: 1991–2000.
    1. Yang J, Wang ZH, Chen JJ, et al. Clinical detection of polymerase gene of SARS‐associated coronavirus. Di Yi Jun Yi Da Xue Xue Bao 2003; 23: 424–427.
    1. Che XY, Hao W, Qiu LW, et al. Antibody response of patients with severe acute respiratory syndrome (SARS) to nucleocapsid antigen of SARS‐associated coronavirus. Di Yi Jun Yi Da Xue Xue Bao 2003; 23: 637–639.
    1. Enserink M. SARS in China. The big question now: will it be back? Science 2003; 301: 299.
    1. Enserink M. Infectious diseases: Singapore lab faulted in SARS case. Science 2003; 301: 1824.
    1. Ding Y, Wang HJ, Shen H, et al. Study on etiology and pathology of severe acute respiratory syndrome. Zhonghua Bing Li Xue Za Zhi 2003; 32: 195–200.
    1. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 1992; 357: 420–422.
    1. Delmas B, Gelfi J, L'Haridon R, et al. Aminopeptidase N is a major receptor for the entero‐pathogenic coronavirus TGEV. Nature 1992; 357: 417–420.
    1. Kontoyiannis DP, Pasqualini R, Arap W. Aminopeptidase N inhibitors and SARS. Lancet 2003; 361: 1558.
    1. Harmer D, Gilbert M, Borman R, et al. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107–110.
    1. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome‐associated coronavirus infection. Gastroenterology 2003; 125: 1011–1017.
    1. Rados C. SARS: protecting against a deadly disease. FDA Consum 2003; 37: 14–17.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi